Download Free Medical Attention-deficit and Hyperactivity Disorder Best Practice Protocols PowerPoint Presentation

Attention-deficit and Hyperactivity Disorder Best Practice Protocols PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Pediatrics, which is titled "Attention-deficit and Hyperactivity Disorder: Best Practice Protocols", to find best practice protocols for Attention-deficit and Hyperactivity Disorder.

Tags : Pediatrics, Attention-deficit, Hyperactivity Disorder, Best Practice Protocols

Published on : Aug 03, 2021 | Views : 1120 | Downloads : 1

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Attention-deficit/Hyperactivity Disorder:Best Practice Protocols Elizabeth A. Lowenhaupt, MD, FAAP PCMH-Kids Behavioral Health Learning CollaborativeApril 27, 2016
Slide 2-

DISCLOSURE The commercial entities with which I/we have relationships do not produce health-care related products or services relevant to the content I am presenting. This presentation does include discussion of medication use which is “off-label”, which I will identify as such.
Slide 3-

GOALS To provide resources and references for providers, patients, and their families; To review the clinical practice guidelines/(parameters) established by the American Academy of Pediatrics (and American Academy of Child & Adolescent Psychiatry) for the assessment and treatment of attention-deficit/hyperactivity disorder; and To set the scene for more in-depth case discussion to follow.
Slide 4-

RESOURCES American Academy of Pediatrics (AAP) Clinical Practice Guideline http://pediatrics.aappublications.org/content/pediatrics/early/2011/10/14/peds.2011-2654.full.pdf American Academy of Child & Adolescent Psychiatry (AACAP) Practice Parameter http://www.jaacap.com/article/S0890-8567(09)62182-1/pdf AACAP ADHD Resource Center http://www.aacap.org/AACAP/Families_and_Youth/Resource_Centers/ADHD_Resource_Center/Home.aspx Parent Medication Guide (AACAP, APA) http://www.parentsmedguide.org/parentguide_english.pdf
Slide 5-

REFERENCES AAP Clinical Practice Guideline ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents (2011). Pediatrics: 128 (5), pp. 1 – 16. AACAP Practice Parameter Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder (2007). JAACAP, 46 (7): 894-921. Distributed article Southammakosane, C & Schmitz K (2015). Pediatric psychopharmacology for treatment of ADHD, depression, and anxiety. Pediatrics, 136 (2): 351-359.
Slide 6-

American Academy of Pediatrics:Clinical Practice Guideline Published in 2000 (recommendations for diagnosis & evaluation) Published in 2001 (recommendations for treatment) Revised in 2011 Intended to be integrated with broader algorithms developed as part of the mission of the AAP Task Force on Mental Health Based on multilevel, systematic review of the literature as evidence base for both diagnosis & treatment Acknowledges implementation challenges (payment and time, access to mental health clinicians, cultural differences, etc.)
Slide 7-

American Academy of Pediatrics: Clinical Practice Guideline ACTION STATEMENTS “The primary care clinician should….”
Slide 8-

American Academy of Pediatrics: Clinical Practice Guideline ACTION STATEMENTS “The primary care clinician should….” Initiate an evaluation for ADHD for any child 4 through 18 years of age who presents with academic or behavioral problems and symptoms of inattention, hyperactivity, or impulsivity
Slide 9-

American Academy of Pediatrics: Clinical Practice Guideline ACTION STATEMENTS “The primary care clinician should….” Initiate an evaluation for ADHD for any child 4 through 18 years of age who presents with academic or behavioral problems and symptoms of inattention, hyperactivity, or impulsivity Determine that DSM-IV criteria have been met
Slide 10-

American Academy of Pediatrics: Clinical Practice Guideline ACTION STATEMENTS “The primary care clinician should….” Initiate an evaluation for ADHD for any child 4 through 18 years of age who presents with academic or behavioral problems and symptoms of inattention, hyperactivity, or impulsivity Determine that DSM-IV criteria have been met Include assessment for other conditions that might coexist with ADHD
Slide 11-

American Academy of Pediatrics: Clinical Practice Guideline ACTION STATEMENTS “The primary care clinician should….” Initiate an evaluation for ADHD for any child 4 through 18 years of age who presents with academic or behavioral problems and symptoms of inattention, hyperactivity, or impulsivity Determine that DSM-IV criteria have been met Include assessment for other conditions that might coexist with ADHD Recognize ADHD as a chronic condition
Slide 12-

American Academy of Pediatrics: Clinical Practice Guideline ACTION STATEMENTS “The primary care clinician should….” Initiate an evaluation for ADHD for any child 4 through 18 years of age who presents with academic or behavioral problems and symptoms of inattention, hyperactivity, or impulsivity Determine that DSM-IV criteria have been met Include assessment for other conditions that might coexist with ADHD Recognize ADHD as a chronic condition Consider treatment based on patient’s age
Slide 13-

American Academy of Pediatrics: Clinical Practice Guideline ACTION STATEMENTS “The primary care clinician should….” Initiate an evaluation for ADHD for any child 4 through 18 years of age who presents with academic or behavioral problems and symptoms of inattention, hyperactivity, or impulsivity Determine that DSM-IV criteria have been met Include assessment for other conditions that might coexist with ADHD Recognize ADHD as a chronic condition Consider treatment based on patient’s age Titrate doses of medication to achieve maximum benefit with minimum adverse effects
Slide 14-

American Academy of Pediatrics: Clinical Practice Guideline ACTION STATEMENTS
Slide 15-

American Academy of Pediatrics: Clinical Practice Guideline ACTION STATEMENTS “The primary care clinician should….” Initiate an evaluation for ADHD for any child 4 through 18 years of age who presents with academic or behavioral problems and symptoms of inattention, hyperactivity, or impulsivity
Slide 16-

ADHDEvaluation Patient/parent interview Standardized behavior rating scales (patient, parent, and/or teacher) EXAMPLES: ADHD Rating Scale Child Behavior Checklist (CBCL) Conners Parent/Teacher Rating Scale-Revised Conners Wells Adolescent Self-Report Scale Swanson, Nolan, and Pelham (SNAP-IV) Vanderbilt ADHD Diagnostic Parent/Teacher Scales
Slide 17-

ADHDEvaluation Psychological testing if academic impairment seems unrelated to ADHD or in addition to it Assessment of intellectual ability (IQ) Academic achievement testing Further work-up may be recommended following psychological testing Neuropsychological testing Speech-language assessment
Slide 18-

American Academy of Pediatrics: Clinical Practice Guideline ACTION STATEMENTS “The primary care clinician should….” Initiate an evaluation for ADHD for any child 4 through 18 years of age who presents with academic or behavioral problems and symptoms of inattention, hyperactivity, or impulsivity Determine that DSM-IV criteria have been met
Slide 19-

DSM-5 (effective May, 2013)Changes to ADHD from DSM-IV Diagnostic criteria similar same 18 symptoms divided into two symptom domains (inattention and hyperactivity/impulsivity), at least six symptoms in one domain required Presentation specifiers instead of sub-types (but same ones)
Slide 20-

DSM-5 (effective May, 2013)ADHD Sub-types  Presentations Combined symptoms of both inattention and hyperactivity-impulsivity for past 6 months Predominantly Inattentive symptoms of inattention but not hyperactivity-impulsivity for past 6 months Predominantly Hyperactive-Impulsive symptoms of hyperactivity-impulsivity but not inattention for past 6 months
Slide 21-

DSM-5 (effective May, 2013)ADHD Diagnostic Criteria Symptoms in one category or both Minimum number of symptoms over past 6 months 6 or more up to age 16 5 or more ages 17 and older Inappropriate for developmental level Disruptive (if hyperactive-impulsive symptoms)
Slide 22-

DSM-5 (effective May, 2013)ADHD Diagnostic Criteria Hyperactive-impulsive presentation: Fidgets with hands or feet or squirms in chair Has difficulty remaining seated Runs about or climbs excessively in children; extreme restlessness in adults Difficulty engaging in activities quietly Acts as if driven by a motor; adults will often feel inside like they were driven by a motor Talks excessively Blurts out answers before questions have been completed Difficulty waiting or taking turns Interrupts or intrudes upon others
Slide 23-

DSM-5 (effective May, 2013)ADHD Diagnostic Criteria Hyperactive-impulsive presentation: Fidgets with hands or feet or squirms in chair Has difficulty remaining seated Runs about or climbs excessively in children; extreme restlessness in adults Difficulty engaging in activities quietly Acts as if driven by a motor; adults will often feel inside like they were driven by a motor Talks excessively Blurts out answers before questions have been completed Difficulty waiting or taking turns Interrupts or intrudes upon others Inattentive presentation: Fails to give close attention to details or makes careless mistakes Has difficulty sustaining attention Does not appear to listen Struggles to follow through on instruction Has difficulty with organization Avoids or dislikes tasks requiring a lot of thinking Loses things Is easily distracted Is forgetful in daily activities.
Slide 24-

DSM-5 (effective May, 2013)Changes to ADHD from DSM-IV Cross-situational requirement strengthened to “several” symptoms in each setting Onset now “several inattentive or hyperactive-impulsive symptoms were present prior to age 12” (as compared to 7) Co-morbid diagnosis with autism allowed Adult diagnosis threshold lowered to only five symptoms Examples added to criterion items to facilitate application across lifespan Location in DSM-5 - placed in neurodevelopmental disorders chapter
Slide 25-

American Academy of Pediatrics: Clinical Practice Guideline ACTION STATEMENTS “The primary care clinician should….” Initiate an evaluation for ADHD for any child 4 through 18 years of age who presents with academic or behavioral problems and symptoms of inattention, hyperactivity, or impulsivity Determine that DSM-IV criteria have been met ……AND rule-out alternative causes
Slide 26-

ADHDDifferential Diagnosis Underlying medical conditions Traumatic brain injury Encephalopathy Metabolic abnormality (e.g. hyperthyroidism) Toxic exposure (e.g. lead exposure, fetal alcohol syndrome, etc.) Other developmental disorders Learning or language disorder Autism spectrum disorder Sleep disorder Other psychiatric disorders Anxiety, depression, or other mood disorders Psychotic disorders Substance use disorders Trauma and/or psychosocial stressors
Slide 27-

American Academy of Pediatrics: Clinical Practice Guideline ACTION STATEMENTS “The primary care clinician should….” Initiate an evaluation for ADHD for any child 4 through 18 years of age who presents with academic or behavioral problems and symptoms of inattention, hyperactivity, or impulsivity Determine that DSM-IV criteria have been met Include assessment for other conditions that might coexist with ADHD
Slide 28-

ADHDCo-Morbidity Emotional/behavioral disorders Anxiety Depression Oppositional defiant Conduct Substance use Developmental disorders Learning Language Other neurodevelopmental disorders (autism, etc.) Physical conditions Tics Sleep apnea
Slide 29-

American Academy of Pediatrics: Clinical Practice Guideline ACTION STATEMENTS “The primary care clinician should….” Initiate an evaluation for ADHD for any child 4 through 18 years of age who presents with academic or behavioral problems and symptoms of inattention, hyperactivity, or impulsivity Determine that DSM-IV criteria have been met Include assessment for other conditions that might coexist with ADHD Recognize ADHD as a chronic condition
Slide 30-

ADHD“Recognize as a chronic condition” Follow principles of “chronic care model” and “medical home” Consider issues of treatment compliance Possibility that parent may also have ADHD Ongoing bidirectional communication, collaborative goal-setting, etc. Patient Parent Teacher/school Mental health providers
Slide 31-

American Academy of Pediatrics: Clinical Practice Guideline ACTION STATEMENTS “The primary care clinician should….” Initiate an evaluation for ADHD for any child 4 through 18 years of age who presents with academic or behavioral problems and symptoms of inattention, hyperactivity, or impulsivity Determine that DSM-IV criteria have been met Include assessment for other conditions that might coexist with ADHD Recognize ADHD as a chronic condition Consider treatment based on patient’s age
Slide 32-

ADHDTreatment Behavior therapy School programming and supports Medication FDA-approved “off label” Treatment of co-morbidity Treatment of parents
Slide 33-

ADHDTreatment (varies by age) Preschool (4-5 years) School-aged (6-11 years) Adolescent (12 – 18 years)
Slide 34-

ADHDTreatment (varies by age) Preschool (4-5 years) First-line treatment = evidence-based parent- and/or teacher-administrated behavior therapy Consider medication if no significant improvement AND moderate-to-severe disturbance in function OR if benefits outweigh risks when no behavior therapy available Best evidence for methylphenidate FDA approval only for dextroamphetamine Lower doses needed due to side effects Concern for decreasing growth velocity (worst during first 2 years of treatment, total range of 1-2 cm)
Slide 35-

ADHDTreatment (varies by age) School-aged children (6-11 years) Recommend FDA-approved medication AND evidence-based parent- and/or teacher-administered behavior therapy Either one ok on its own Include school program/placement as part of treatment plan
Slide 36-

ADHDTreatment (varies by age) Adolescent (12-18 years) Recommend FDA-approved medication AND evidence-based parent- and/or teacher-administered behavior therapy Medication alone ok Assess for symptoms of substance abuse Consider in making diagnosis Consider in recommending treatment  POTENTIAL FOR ABUSE/DIVERSION Consider risks for driving when developing medication treatment plan
Slide 37-

ADHDTreatment Behavior therapy School programming and supports Medication FDA-approved “off label” Treatment of co-morbidity Treatment of parents
Slide 38-

ADHDTreatment Behavior therapy School programming and supports Medication FDA-approved “off label” Treatment of co-morbidity Treatment of parents
Slide 39-

ADHDTreatment Behavior therapy Parent- or teacher- training techniques (often taught in group format) Evidence-based treatments: Behavioral parent training (BPT) Behavioral classroom management Behavioral peer interventions (BPI)  May be used alone or in conjunction with medication
Slide 40-

ADHDTreatment Behavior therapy School programming and supports Medication FDA-approved “off label” Treatment of co-morbidity Treatment of parents
Slide 41-

ADHDTreatment Behavior therapy School programming and supports Medication FDA-approved “off label” Treatment of co-morbidity Treatment of parents
Slide 42-

ADHDTreatment Medication FDA-approved Stimulants (most effective) Non-stimulants (less effective) “off label”
Slide 43-

ADHDTreatment (Medications – FDA-approved) STIMULANTS Classes: Amphetamine Methylphenidate Long-acting vs. short-acting Dosing parameters* Side effects & management* *reviewed in detail in Pediatric Psychopharmacology reference or AAP Clinical Practice Guideline Supplemental materials
Slide 44-

ADHDTreatment (Medications – FDA-approved) STIMULANTS: side effects Most common Appetite loss Abdominal pain Headaches Sleep disturbance Decreasing growth velocity Uncommon but severe Hallucinations & psychosis Sudden cardiac death Mood lability & dysphoria (preschool)
Slide 45-

ADHDTreatment (Medications – FDA-approved) NON-STIMULANTS Best evidence from top to bottom: 1) Atomoxetine (selective norepinephrine-reuptake inhibitor) 2) *Extended-release guanfacine (selective alpha-2-adrenergic agonist) 3) *Extended-release clonidine (selective alpha-2-adrenergic agonist) *Evidence to support efficacy as mono-therapy OR adjunctive therapy
Slide 46-

ADHDTreatment (Medications – FDA-approved) NON-STIMULANTS: side effects Atomoxetine Somnolence GI symptoms (including decreased appetite) Suicidal ideation (Black Box Warning) Hepatitis (rare) Alpha-2 agonists Somnolence (esp. clonidine) Dry mouth Hypotension (or hypertension on sudden discontinuation)
Slide 47-

ADHDTreatment Behavior therapy School programming and supports Medication FDA-approved “off label” Treatment of co-morbidity Treatment of parents
Slide 48-

American Academy of Pediatrics: Clinical Practice Guideline ACTION STATEMENTS “The primary care clinician should….” Initiate an evaluation for ADHD for any child 4 through 18 years of age who presents with academic or behavioral problems and symptoms of inattention, hyperactivity, or impulsivity Determine that DSM-IV criteria have been met Include assessment for other conditions that might coexist with ADHD Recognize ADHD as a chronic condition Consider treatment based on patient’s age Titrate doses of medication to achieve maximum benefit with minimum adverse effects
Slide 49-

ADHDTreatment (Medication Management Tips) Starting class, formulation, and dose based on age, symptom pattern, insurance reimbursement Can titrate every 3-7 days at first Titrate to “maximum doses that control symptoms without adverse effects”
Slide 50-

ADHDTreatment (Medication Management Tips) Routine monitoring for benefits and adverse effects Follow-up visits (initially every 30 days) Phone availability for questions/concerns Refill plan (including consideration of controlled substance) Reassessment with parents & school (verbal communication, rating scales, etc.)
Slide 51-

ADHDTreatment (Medication Management Tips) Psychoeducation for patient and parents Timing (immediate benefit likely but process may take awhile) May need to increase dose sometimes May need to change meds sometimes Realistic expectations around anticipated benefits
Slide 52-

RESOURCES American Academy of Pediatrics (AAP) Clinical Practice Guideline http://pediatrics.aappublications.org/content/pediatrics/early/2011/10/14/peds.2011-2654.full.pdf American Academy of Child & Adolescent Psychiatry (AACAP) Practice Parameter http://www.jaacap.com/article/S0890-8567(09)62182-1/pdf AACAP ADHD Resource Center http://www.aacap.org/AACAP/Families_and_Youth/Resource_Centers/ADHD_Resource_Center/Home.aspx Parent Medication Guide (AACAP, APA) http://www.parentsmedguide.org/parentguide_english.pdf
Slide 53-

REFERENCES AAP Clinical Practice Guideline ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents (2011). Pediatrics: 128 (5), pp. 1 – 16. AACAP Practice Parameter Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder (2007). JAACAP, 46 (7): 894-921. Distributed article Southammakosane, C & Schmitz K (2015). Pediatric psychopharmacology for treatment of ADHD, depression, and anxiety. Pediatrics, 136 (2): 351-359.
Slide 54-

Case Presentation & Panel Discussion
Slide 55-

Case presentation & Panel discussion Three different cases to review (30 minutes per case) Focus on different aspects of ADHD assessment & treatment across three different stages of development FORMAT (for each case): Brief case presentation Tables discuss for 10 minutes Facilitated audience discussion with input from panel members Panel wrap-up with key points
Slide 56-

CASE #1 Hannah presents to your office for her 3-year old well child visit. Screening for Wellness in Young Children (SWYC) indicates that her mother has behavioral concerns. Mother reports that Hannah is “hyper” and doesn’t listen. Hannah’s mother is afraid to send her to preschool because she can’t sit still and would like your help.
Slide 57-

CASE #2 Joey is an 8-year old boy whose parents bring him in to your office when they find out he has to repeat the second grade. Joey has been struggling to learn how to read Joey’s teachers report that he is disruptive in class, speaks out in turn, and never has his homework finished. Joey’s parents are asking for your help in figuring out what’s wrong with him and what they should do about school.
Slide 58-

CASE #3 Sam is a 14-year old patient of yours who presents with increasing school difficulty. Sam was struggling in 7th grade and is still having trouble in 8th. Sam often shows up late to school and has already missed 12 days this semester. The parents just got a letter from the school truancy officer and want your help in figuring out what is wrong and what they can do about it.